



ANDA 090526

Barr Laboratories, Inc.
Attention: Scott D. Tomskey
Vice President, N.A. Generics Regulatory Affairs
425 Privet Road
Horsham, PA 19044

Dear Sir:

This is in reference to your abbreviated new drug application (ANDA) dated March 28, 2008 and accepted for filing on August 19, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Oxybutynin Transdermal System, 3.9 mg/day (Extended-release).

Reference is also made to your amendments dated August 18, and September 29, 2008; February 6, and August 10, 2009; March 25, July 15, October 21, and November 5, 2010; June 24 and November 10, 2011; January 11, February 15, and July 3, 2012; and April 1, September 11, October 10, and December 26, 2013.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Oxybutynin Transdermal System, 3.9 mg/day (Extended-release), to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Oxytrol[®] Transdermal System, 3.9 mg/day, of Watson Laboratories (Utah), Inc. (Watson).

Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA. The "interim" dissolution specifications are as follows:

The dissolution testing should be conducted in 900 mL of pH 4.5 phosphate buffer at 32°C ± 0.5°C using USP apparatus V (paddle over disk) at 50 rpm.

The test product should meet the following "interim" specifications:

1 Hour:  (b) (4)
4 Hours: 
24 Hours: 

The "interim" dissolution test(s) and tolerances should be finalized by submitting dissolution data from the first three production size batches. These data should be submitted as a "Special Supplement - Changes Being Effected" if there are no revisions to be made to the "interim" specifications, or if the final specifications are tighter than the "interim" specifications. In all other instances, the information should be submitted in the form of a Prior Approval Supplement.

The RLD upon which you have based your ANDA, Watson's Oxytrol® Transdermal System, is subject to periods of patent protection. The following patents and their expiration dates are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for this drug product:

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
5,601,839 (the '839 patent)	April 26, 2015
5,834,010 (the '010 patent)	April 26, 2015
6,743,441 (the '441 patent)	April 26, 2020
7,081,249 (the '249 patent)	April 26, 2020
7,081,250 (the '250 patent)	April 26, 2020
7,081,251 (the '251 patent)	April 26, 2020
7,081,252 (the '252 patent)	April 26, 2020
7,179,483 (the '483 patent)	April 26, 2020

Your ANDA contains paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the Act stating that each of these patents is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Oxybutynin Transdermal System, 3.9 mg/day (Extended-release), under this ANDA. You have notified the agency that Barr Laboratories, Inc. (Barr) complied with the requirements of section 505(j)(2)(B) of the Act, and that litigation was initiated against Barr for infringement of each patent listed above within the statutory 45-day period in the United States District Court for the District of Delaware [Watson Laboratories, Inc. v. Barr Laboratories, Inc., Civil Action No. 08-CV-793 (GMS)]. You have further notified the agency that this case has been dismissed.

With respect to 180-day generic drug exclusivity, we note that Barr was the first ANDA applicant for Oxybutynin Transdermal System, 3.9 mg/day (Extended-release), to submit a substantially complete ANDA with a paragraph IV certification. Therefore, with this approval, Barr may be eligible for 180 days of generic drug exclusivity for Oxybutynin Transdermal System, 3.9 mg/day (Extended-release). This exclusivity, which is provided for under section 05(j)(5)(B)(iv) of the Act, would begin to run from the date _____ ng

(b)(4)

Please submit correspondence to this ANDA informing the agency of the date commercial marketing begins.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b) (3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date

specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

{See appended electronic signature page}

Kathleen Uhl, M.D.
Acting Director
Office of Generic Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L WEST

03/04/2014

Deputy Director, Office of Generic Drugs, for
Kathleen Uhl, M.D.